Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Pharmaceuticals

Delayed Japan Exchange 07:00:00 19/06/2024 BST 5-day change 1st Jan Change
5,337 JPY +0.49% Intraday chart for Daiichi Sankyo Co., Ltd. -5.14% +37.84%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
AstraZeneca Signs Mobile Support Collaboration for Breast Cancer Patients MT
Daiichi Sankyo to Dispose of 320 Million Yen Worth of Shares as Restricted Shares Remuneration MT
Daiichi Sankyo Buys Back Shares Worth Over 29 Billion Yen in May MT
Transcript : Daiichi Sankyo Company, Limited - Special Call
AstraZeneca Says Potential Breast Cancer Treatment Reduces Risk of Disease Progression by up to 38% MT
AstraZeneca Reports Positive Results for Metastatic Breast Cancer Drug MT
Astra's Enhertu breast cancer trial shows 'unprecedented' results RE
Astra's Enhertu delays breast cancer in patients with low HER2 levels RE
Astrazeneca Safety Profile Of Enhertu Was Consistent With Previous Breast Cancer Clinical Trials With No New Safety Concerns Identified RE
Daiichi Sankyo and AstraZeneca PLC Provides Positive Results from the DESTINY-Breast06 Phase 3 Trial CI
AstraZeneca and Daiichi Sankyo Announce Positive Results from the DESTINY-Breast06 Phase III Trial Showed That ENHERTU Metastatic Breast Cancer and the Overall Trial Population CI
RevolKa Signs Master Service Agreement with Daiichi Sankyo CI
AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients DJ
AstraZeneca, Daiichi Sankyo’s Lung Cancer Drug Shows Mixed Results in Late-stage Trial MT
AstraZeneca's Lung Cancer Drug Shows Clinically Meaningful Improvement in Overall Survival MT
Astra, Daiichi hail positive survival data for Dato-DXd AN
Daiichi Sankyo and AstraZeneca PLC Provides an update on TROPION-Lung01 Phase 3 Trial CI
Jefferies Adjusts Daiichi Sankyo’s Price Target to 6,600 Yen From 5,600 Yen, Keeps at Buy MT
AstraZeneca to build $1.5-bln cancer drug plant in Singapore RE
Merck to present new oncology data CF
IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court MT
Japan's Nikkei closes at 3-week high on US rate-cut outlook, tech boost RE
Japan's Nikkei climbs on Fed rate-cut outlook, tech boost RE
Remsons, Daiichi Infotainments Form Joint Venture MT
AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement MT
Chart Daiichi Sankyo Co., Ltd.
More charts
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis; - other (0.2%): primarily real estate activities. Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
5,311 JPY
Average target price
6,077 JPY
Spread / Average Target
+14.42%
Consensus
  1. Stock Market
  2. Equities
  3. 4568 Stock
  4. News Daiichi Sankyo Co., Ltd.
  5. Jefferies Adjusts Daiichi Sankyo’s Price Target to 6,600 Yen From 5,600 Yen, Keeps at Buy
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW